Drugs / Autologous EBV-specific Cytotoxic T Lymphocytes (CTL)
Autologous EBV-specific Cytotoxic T Lymphocytes (CTL)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02912897 | Jan 2021 → Nov 2028 expected | multiple sclerosis | Nantes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) | “Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL)” NCT02912897 ↗ |
| Action | Restore | “in order to finally restore an efficient control of EBV in MS patients” NCT02912897 ↗ |
| Modality | Cell therapy | “Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL)” NCT02912897 ↗ |